Surprisingly, in prostate cancer, after analyzing radical prostatectomy tissues by immunohistochemistry (IHC) and microarray in a multicenter cohort, high CXCL16, CXCR6 and CXCL16-CXCR6 co-expression were found to be independent prognostic factors for poorer clinical failure-free survival (the progression of local symptoms or metastasis to bone, visceral organs or lymph nodes), like other anatomopathological features such as a Gleason > 7, vascular infiltration and positive surgical margins [116]. This evidence concerns the gene CXCL16 and prostate cancer.